Table 2.
Prior vaccination | Yes | No | p ∗ | ||
---|---|---|---|---|---|
n | % | n | % | ||
Patient number | 35 | 50 | 35 | 50 | |
M stage | |||||
M1A | 8 | 23 | 3 | 9 | 0.3 |
M1B | 8 | 23 | 10 | 28 | |
M1C | 19 | 54 | 22 | 63 | |
Dose | |||||
3 mg/kg | 30 | 86 | 32 | 91 | 0.45 |
10 mg/kg | 5 | 14 | 3 | 9 | |
Reinduction | 4 | 12 | 3 | 9 | |
Treatment stopped for toxicity | 5 | 14 | 2 | 6 | |
Objective response | |||||
CR | 3 | 9 | 3 | 9 | 0.03 ∗∗ |
PR | 10 | 29 | 4 | 11 | |
S | 6 | 17 | 1 | 3 | |
P | 16 | 46 | 27 | 77 | |
Survival data | |||||
Median OS (months) | 31 (3–47) | 9 (2–50) | 0.007 | ||
3-year survival rate | 46% | 19% |
CR: complete response, PR: partial response, S: stable disease, and P: progression.
∗Pearson chi square (two-sided) test.
∗∗ p value for progression (P) versus any benefit (CR, PR, and S).